Welcome to our dedicated page for DSS news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on DSS stock.
DSS, Inc. (NYSE American: DSS) is a multinational conglomerate with a diversified business portfolio encompassing nine distinct divisions: Product Packaging, Biotechnology, Consumer Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Secure Living, Digital Transformation, and Alternative Energy. Established over 25 years ago, DSS has a long-standing reputation in anti-counterfeit, authentication, and diversion protection technologies, offering custom solutions to safeguard against product diversion, counterfeit, theft, and other costly occurrences. Their innovative technologies, backed by numerous patents, are utilized by corporations, governments, and financial institutions worldwide.
Recently, DSS has focused on expanding its value through strategic acquisitions and periodic IPO spinoffs. Under the leadership of Frank Heuszel, DSS has built a diversified portfolio aimed at driving profitability and growth. Notable subsidiaries include DSS Wealth Management, which advises the AmericaFirst Quantitative Funds, and Premier Packaging, specializing in innovative fiber-based packaging solutions.
In recent developments, DSS appointed Jim Monaghan as Chief Operating Officer and Chief Compliance Officer, and Michael Cheah as Portfolio Manager & Head of Fixed Income at DSS Wealth Management. Both additions bring over 30 years of industry experience and are expected to enhance DSS's investment strategies and compliance standards. Moreover, DSS is preparing for the IPO of its subsidiary, Impact Biomedical, which promises to reinforce the company's growth trajectory.
DSS's recent accomplishments include a successful legal defense of their ‘040 patent in the Federal Circuit Court against Nichia Corp., further solidifying their strong IP portfolio. Additionally, Chairman Heng Fai Ambrose Chan's recent acquisition of 672,173 shares underscores his confidence in DSS's strategic direction and market potential.
For continuous updates and more detailed information, visit the official website at www.dssworld.com and follow their latest news and developments on Twitter at @docsecuritysys and @authentisuite.
DSS, a multinational company, announced it will highlight its strong revenue growth and future spinoffs at the Emerging Growth Virtual Conference on April 19, 2023. COO Jason Grady will present from 1:45-2:15 PM ET. Investors can register to watch the presentation here. The event will also include a Q&A session, allowing shareholders to submit questions in advance via IR@dssworld.com. DSS operates across nine sectors, focusing on increasing shareholder value through strategic acquisitions and IPO spinoffs. Interested parties can receive future updates by emailing IR@dssworld.com. Learn more about DSS by visiting www.dssworld.com.
DSS, Inc. (NYSE American: DSS) announced a shareholder letter detailing its business strategy and performance. The company reported a more than 100% increase in trailing 12-month revenues since 2021 and total assets approaching $265 million. DSS employs a three-stage development process focused on acquisitions, revenue generation, and profitability, with plans for potential IPOs of its subsidiaries. Premier Packaging's new facility has boosted revenue by nearly 19% year-over-year. Upcoming milestones include various liquidity events and an anticipated dividend strategy for shareholders, reinforcing the vision for value creation.
On October 19, 2022, DSS announced that its subsidiary, Impact BioMedical, will be featured in a documentary titled "The BioQuest". The film highlights GRDG Sciences' innovative research and technologies aimed at solving global health issues. GRDG's recent projects, including the multi-year Sombrero initiative, have led to several breakthrough technologies such as Equivir and antimicrobial bioplastics. The documentary, produced by Diamond Studios, begins filming on December 3, 2022, with aims to present GRDG's mission of creating impactful health solutions.
DSS, Inc. (NYSE American: DSS) announced on August 30, 2022, that it received a notice for non-compliance with NYSE American's listing requirements due to its inability to timely file the Form 10-Q. The company has a possible 12 months to rectify this issue, with an initial automatic six-month period. DSS cited challenges that prevented the timely filing and is actively working to resolve these issues. With a diversified portfolio across various sectors, DSS aims to drive profitability and shareholder value despite these reporting delays.
DSS announced a significant advancement in biotechnology with the development of a Quantum-based antihistamine by its subsidiary, Impact Biomedical, and research partner, GRDG. This new compound could be up to 50 times more effective than existing drugs, offering lower toxicity through reduced dosages. The initiative aims to tackle the looming patent cliff in the pharmaceutical industry, where over $200 billion in revenue is at risk from 2025-2030 due to expiring patents. The Quantum Project may positively reshape drug development and holds potential for global health improvements.
On July 21, 2022, DSS announced that its subsidiary Global BioLife entered a licensing agreement with ProPhase BioPharma for the Linebacker portfolio, consisting of patented small molecule PIM kinase inhibitors. This agreement marks a significant milestone for Impact BioMedical and aims at further development in oncology, with ProPhase's CEO highlighting multi-billion-dollar potential. Pre-clinical testing indicates Linebacker could effectively cross the blood-brain barrier and tackle various diseases, including cancer.
DSS, a multinational company, announced the appointment of two independent directors to its Board: Frankie Wong and Joanne Wong Hiu Pan. Frankie Wong brings over 20 years of experience in financial reporting and has served in CFO roles at various listed companies. Joanne Wong has over 15 years in the financial industry as an investment manager. CEO Frank D. Heuszel stated that their addition enhances the board's expertise in legal, operations, financing, and more, supporting DSS's vision across its nine business divisions.
Impact Biomedical, a subsidiary of DSS, has signed a license agreement with ProPhase Labs for Equivir, a treatment aimed at reducing the occurrence and severity of viral outbreaks. With human clinical trials set to commence soon, Equivir, which has received two U.S. patents, is believed to block viral entry into host cells. The partnership leverages ProPhase's extensive experience in health product distribution, potentially expediting Equivir's market entry. The treatment may combat various viruses, including influenza and SARS-CoV-2, addressing critical global health needs.
DSS, Inc. announced that its subsidiary, Global BioLife, received a patent in China for its innovative mosquito repellant technology, 3F™. This formulation utilizes botanical oils to incapacitate mosquito receptors, enhancing its effectiveness over traditional repellants. The global mosquito repellant market is projected to grow from $6.9 billion in 2021 to $10.9 billion by 2028, with China recognized as a leading market. Frank Heuszel, President of Impact BioMedical, emphasized the technology's potential for licensing and commercialization, which could drive shareholder value.
DSS, Inc. (NYSE American: DSS) announced an upcoming interview with COO Jason Grady on The RedChip Money Report, airing on Bloomberg U.S. on May 7 at 7 p.m. ET. The show provides insights into small cap investing and features executives from public companies. DSS operates nine business divisions, focusing on strategic acquisitions and IPO spinoffs to enhance shareholder value. The company's diversified portfolio aims to drive profitability in high-growth sectors.
FAQ
What is the current stock price of DSS (DSS)?
What is the market cap of DSS (DSS)?
What does DSS, Inc. specialize in?
What are the key divisions of DSS, Inc.?
Who are the recent key hires at DSS Wealth Management?
What are some recent achievements of DSS, Inc.?
What is the significance of the Impact Biomedical IPO?
How does DSS, Inc. enhance shareholder value?
How can I stay updated on DSS, Inc. news?
What makes DSS, Inc.'s Product Packaging division unique?
Who is the CEO of DSS, Inc.?
What recent investment did Chairman Heng Fai Ambrose Chan make in DSS?
